Lucid Diagnostics (NASDAQ:LUCD) Upgraded by Wall Street Zen to Hold Rating

Lucid Diagnostics (NASDAQ:LUCD) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

A number of other research firms have also commented on LUCD. Needham & Company LLC reaffirmed a “buy” rating and set a $3.00 price objective on shares of Lucid Diagnostics in a research note on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Lucid Diagnostics in a research note on Monday, December 29th. Finally, Ascendiant Capital Markets upped their target price on shares of Lucid Diagnostics from $8.00 to $8.25 and gave the company a “buy” rating in a report on Wednesday, December 10th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $3.94.

Lucid Diagnostics Stock Performance

LUCD stock opened at $1.12 on Friday. The stock’s 50 day moving average price is $1.30 and its 200 day moving average price is $1.18. The firm has a market cap of $154.20 million, a P/E ratio of -1.17 and a beta of 1.18. Lucid Diagnostics has a 1 year low of $0.95 and a 1 year high of $1.80.

Lucid Diagnostics (NASDAQ:LUCD) last released its quarterly earnings results on Thursday, March 26th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.03). The business had revenue of $1.50 million during the quarter, compared to the consensus estimate of $1.39 million. On average, research analysts predict that Lucid Diagnostics will post -0.84 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in LUCD. Centiva Capital LP acquired a new stake in shares of Lucid Diagnostics during the third quarter worth $25,000. Sprott Inc. acquired a new position in Lucid Diagnostics in the third quarter valued at $25,000. SG Americas Securities LLC acquired a new position in Lucid Diagnostics in the third quarter valued at $26,000. Quadrature Capital Ltd purchased a new position in Lucid Diagnostics during the second quarter worth about $29,000. Finally, Abel Hall LLC purchased a new position in Lucid Diagnostics during the fourth quarter worth about $33,000. Hedge funds and other institutional investors own 74.01% of the company’s stock.

Lucid Diagnostics News Roundup

Here are the key news stories impacting Lucid Diagnostics this week:

• Positive Sentiment: Won expanded access with the U.S. Department of Veterans Affairs and is pushing for Medicare/commercial payer wins, which could materially enlarge addressable market and reimbursement prospects. Lucid Diagnostics signals expanded VA market access and 29% sequential test volume
• Positive Sentiment: Strong test-volume growth: management reported ~29% sequential growth in EsoGuard tests processed (3,664 tests in Q4), indicating improving commercial traction. Q4 2025 Earnings Call Highlights
• Positive Sentiment: Revenue slightly beat consensus ($1.50M reported vs. $1.39M expected), showing top-line improvement versus prior-year quarter. Zacks: Reports Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: Company highlighted strengthened clinical evidence with positive real‑world data (largest reported experience for esophageal precancer detection), which can support adoption and payer discussions. PR Newswire: Business Update & Financial Results
• Positive Sentiment: Analyst backing: Needham reaffirmed a “buy” rating with a $3.00 price target, representing sizable upside from current levels if execution continues. Benzinga: Needham Reaffirms Buy
• Neutral Sentiment: Company hosted a Q4 business update and provided slides/webcast; multiple earnings-call transcripts and slides are available for investors evaluating management commentary and forward guidance. Quarterly Press Release / Slide Deck
• Negative Sentiment: Earnings miss on profitability: Lucid reported a Q4 EPS of -$0.10 vs. consensus -$0.07, a larger-than-expected loss that likely drove near-term selling pressure despite revenue strength. InsiderMonkey: Q4 2025 Earnings Call Transcript

Lucid Diagnostics Company Profile

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.